Pluristem Therapeutics Inc. (PSTI)
PSTIPrice: $1
Fair Value: 🔒
🔒score
Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune diso... more
Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, develo... more
Description
Shares
| Market Cap | $40.85M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | IL | CEO | Yaky Yanay |
| IPO Date | 2007-12-10 | CAGR | — |
| Employees | 153 | Website | www.pluristem.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
PSTI chart loading...
Fundamentals
Technicals
| Enterprise Value | $66.50M | P/E Ratio | -0.68 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 66.75 | P/B Ratio | -9.59 |
| P/CF Ratio | 4.35 | P/FCF Ratio | 3.22 |
| EPS | $-1.46 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | 0.4% |
| Operating Margin | -17.64% | Profit Margin | -7.33% |
| ROE | 0.7% | ROA | -0.27% |
| ROCE | 0.69% | Current Ratio | 0.68 |
| Quick Ratio | 0.68 | Cash Ratio | 0.18 |
| Debt/Equity | -0.99 | Interest Coverage | -25.52 |
| Altman Z Score | -40.95 | Piotroski Score | 5 |